

REMARKS

Changes have been made to the specification on pages 25-27 to delete erroneous sequence identifiers. The specification is further corrected and a Sequence Listing is herein submitted to comply with the requirements of an application containing a nucleotide and/or amino acid sequence 37 C.F.R. §§ 1.821 - 1.825.

Hereto is an attached Sequence Listing in paper and computer readable format. The paper copy and computer readable copy of the Sequence Listing are the same. The Sequence Listing does not include new matter.

Amendments have also been made to the figures so that Figures 1-7 are properly labeled in accordance with 37 C.F.R. §1.84(u)(1). Applicants respectfully submit that the replacement formal drawing sheets are believed to be in compliance with 37 C.F.R. §1.84 and 37 C.F.R. §1.121. Attached hereto are replacement formal drawing sheets for Figs. 1A, 1B, 2A, 2B(i), 2B(ii), 2B(iii), 3A, 3B, 3C, 4, 5, 6A, 6B, 7A, 7B, 7C(i) and 7C(ii).

CONCLUSION

Entry of the Sequence Listing, the replacement formal drawing sheets for Figs. 1A, 1B, 2A, 2B(i), 2B(ii), 2B(iii), 3A, 3B, 3C, 4, 5, 6A, 6B, 7A, 7B, 7C(i) and 7C(ii), corrections to the specification and favorable consideration are respectfully requested.

To the extent necessary, please grant any extension of time deemed necessary for entry of this communication. Please charge any deficient fees, or credit any overpayment of fees, to Deposit Account 500417.

Respectfully submitted,

MCDERMOTT, WILL & EMERY LLP

Date:

June 28, 2004

By:

Kelli N. Watson
Kelli N. Watson
Registration No. 47,170

600 Thirteenth Street, N.W.
Washington, D.C. 20005-3096
(202) 756-8351 (Direct)
(202) 756-8087 (Facsimile)